Abstr 837 Dr Colmegna: Should we use high dose Infleunza vaccine in #RA? Vaccines less effective in RA DB RCT low vs. High dose in 279 RApts. Showed sig. better immune response with high dose vaccine. #ACR18 @RheumNow

#RA #ACR18 @RheumNow Abstr 838: Anti-MDA5 pos DM-ILD has a poor prognosis. survival at 6mo 89% vs 33% with combo imsuppressive (Pred 1mg/kg/d tapering, IVCYC 500-1g/m2; Tacrolimus through 24 wk. 29 pts, historic controls. Hi risk of CMV activation #ACR18 #Myositis @rheumnow

Plenary Abstract 839: Dr Schmukler Chicago. Can we use MDHAQ (multi-dimensional) to identify FM? 84% agreement with 2011 FMS questionnaire - so the answer is Yes! (But what is the ‘gold std’?) @RheumNow #FMS #ACR18

Checkpoint inhibitors explosion of papers in 2018 New and/or exacerbated arthritis, myositis, lupus, sarcoidosis, sjogrens, vasculitis How to treat? - still unknown Year in review - clinical #ACR18 @RheumNow

Q&A 'Over half the GCA patients had LVV+ on PET/CT' [note to self: need to insist on more PET/CT and push for Tocilizumb] #ACR18 @RheumNow #GCA

Abst 884 Jeff Sparks. Predictors of ILD in #RA in 1281 patients: High disease activity, seropositivity - no surprises #ACR18 @RheumNow

Personal observation here: over 25 years of practice I’ve seen disease activity fall and severe ILD become uncommon - but MTX use much more common. Time to rethink! #Acr18 #RA

Abst 2977 Dr Werth Lenabasam - cannabinoid receptor type 2 (CB2) agonist that activates resolution of innate immune responses - effective in reducing interferon beta and gamma in #Dermatomyositis skin biopsies #ACR18

Lisa Sammaritano quoting a patient panel assisting in the development of Reproductive Guidelines for Rheumatology Patients. “My rheumatologist knows me better than my gynecologist.

2789 Ph3 Apremilast for Behcet’s oral ulcers: significantly lower number of OU (P≤0.0015) &reduction in OU pain (P≤0.0035) vs PBO at wks 1-12. APR efficacy sustained at wk28: 62% pts achieved complete response of OU &70% relative reduction in OU pain from BL. #acr18 @rheumnow

RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Eli Lilly. All content chosen and distributed by RheumNow and its faculty.

RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Novartis. All content chosen and distributed by RheumNow and its faculty.